Greater uptake, an alternative reimbursement methodology needed to realize cost-saving potential of oncology biosimilars in the United States.

Biologics are an important treatment option for solid tumors and hematological malignancies but are a primary driver of health care spending growth. The United States has yet to realize the promise of reduced costs via biosimilars because of slow uptake, partially resulting from commercial payer reimbursement models that create economic incentives favoring the prescribing of reference biologics. To examine the economic feasibility of an alternative reimbursement methodology that prospectively shares savings across commercial payers and providers to shift economic incentives in favor of lower-cost oncology biosimilars.

Collect Data, Tell Stories: Utilizing Available Data to Improve Wound Product Selection, Reduce Costs, and Improve Outcomes.

To develop a tool to assist in the evaluation of treatment options based on clinically relevant parameters, thus enabling clinicians to heal patients more efficiently. Outlined here is the prototypic model of a comprehensive analysis tool to compare products by category, accounting for product characteristics, effectiveness data from literature, costs, and patient needs or clinician preferences. The tool is demonstrated with a venous leg ulcer example, and ideas for expanding the tool in the future are provided.